title: [The protective effect of N-acetylcysteine magnesium against liver cirrhosis with portal hypertension in rat].
abstract: OBJECTIVE
  To study the effects of acetylcysteine magnesium on the vasoactive substances and hepatic fibrosis indexes in liver cirrhosis and portal hypertension of rats.
  
  
  METHODS
  The rat liver cirrhosis model was made with 12 microg/kg dimethylnitrosamines. Then acetylcysteine magnesium was injected respectively with 25, 50, and 100 mg x kg(-1) dose daily into abdominal cavity. After 8 weeks treatment, pathological section, TGF-beta1, NO, TNOS and iNOS of hepatic tissue were detected to assess the effect of acetylcysteine magnesium against cirrhosis portal hypertension.
  
  
  RESULTS
  After the DMNA modeling was completed, the HE and Sweet reticulocyte staining of liver pathological section showed that cirrhosis of the liver was in the III-IV phase, the infiltration of lymphocytes and formation of pseudolobuli in liver were alleviated in three acetylcysteine magnesium treatment groups (low, medium, and high dose), and the degree of liver fiber sclerosis in three groups was significantly lower than control group. Compared with control group, TGF-beta1, NO, TNOS and iNOS were significantly reduced in all treatment groups (P < 0.05).
  
  
  CONCLUSIONS
  Acetylcysteine magnesium is probably a distinctive antioxidant which can remove various free radical in body and modulate ligand-dependent signal transduction and the growth of cell. It also have protection in the liver cirrhosis and portal hypertension of rats induced by dimethylnitrosamine.
authors.affiliation: Hangzhou Sixth People's Hospital, Zhejiang 310014, China.
authors.forename: Rang-Xiao
authors.initials: RX
authors.lastname: Zhuang
authors.forename: Fu-Gen
authors.initials: FG
authors.lastname: Wang
authors.forename: Hong-Ping
authors.initials: HP
authors.lastname: Zhou
authors.forename: Ting-Ting
authors.initials: TT
authors.lastname: Shi
authors.forename: Shou-Rong
authors.initials: SR
authors.lastname: Liu
mesh_terms: D000111:Acetylcysteine / Q000627:therapeutic use*; D000818:Animals; D006975:Hypertension, Portal / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D008106:Liver Cirrhosis, Experimental / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D009569:Nitric Oxide / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D053773:Transforming Growth Factor beta1 / Q000032:analysis
chemical_list: D053773:Transforming Growth Factor beta1; D009569:Nitric Oxide; D000111:Acetylcysteine